Product Images Gabapentin

The text describes a figure labeled as "Figure 1" displaying weekly mean pain scores. The figure has a 4-week dose titration period and a 4-week fixed dose period. The treatments mentioned are placebo and Gabapentin at a dose of 3600 mg/day. The baseline and eight weeks are labeled on the x-axis. The y-axis is labeled as mean pain score. The figure suggests that Gabapentin may be statistically significant in reducing pain given the p-value mentioned (**p<0.01) compared to placebo.*

The text describes a chart denoting the weekly mean pain scores for Study 2. The chart consists of three doses; a placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The chart is split into two parts: a three-week dose titration period and a four-week fixed dose period. The chart also indicates that there is a significant difference between the results of Gabapentin and the placebo.*

The text describes the results of two controlled studies on postherpetic neuralgia (PHN), a type of nerve pain that occurs after shingles. The studies compare the effectiveness of two drugs, PBO and GBP, in reducing pain in patients with PHN. The proportion of "responders," or patients who experienced more than a 50% reduction in their pain score, is shown in Figure 3. The study data is presented in three columns, with the first column labeled as "PBO" and the second and third columns labeled as "GBP." Additionally, the text includes asterisks indicating statistical significance with p-values less than 0.01 or 0.001.*

The figure displays the responder rate of patients receiving Gabapentin compared to placebo by dose and study for adjunctive therapy in patients over 12 years old with partial seizures. The daily dose range is between 600-1800 mg. No other information is available.*